Pacira BioSciences Inc. (PCRX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Pacira BioSciences Inc. (PCRX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

20.55

-0.58 (-2.74%)

At close: Jan 14, 2025, 3:59 PM

20.50

-0.24%

After-hours Jan 14, 2025, 04:01 PM EST

undefined% (undefined)

Bid	20.02
Market Cap	948.86M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.98
PE Ratio (ttm)	-10.38
Forward PE	n/a
Analyst	Buy

Ask	22.4
Volume	418,718
Avg. Volume (20D)	698,114
Open	21.12
Previous Close	21.13
Day's Range	20.33 - 21.41
52-Week Range	11.16 - 34.01
Beta	undefined

About PCRX

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted ner...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Feb 3, 2011

Employees 711

Stock Exchange NASDAQ

Ticker Symbol PCRX

Website https://www.pacira.com

Analyst Forecast

According to 10 analyst ratings, the average rating for PCRX stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 16.79% from the latest price.

Buy 60.00%

Hold 20.00%

Sell 20.00%

Stock Forecasts

Next Earnings Release

Pacira BioSciences Inc. is scheduled to release its earnings on Feb 27, 2025, before market opens.
Analysts project revenue of $178.47M, reflecting a -1.53% YoY shrinking and earnings per share of 0.82, making a -7.87% decrease YoY.

Why Price Moved

5 days ago · Source

+11.09%

Pacira Biosciences shares are trading higher after... Unlock content with Pro Subscription

5 months ago · Source

-47.67%

Pacira BioSciences shares are trading lower after the U.S. District Court for the District of New Jersey found that Patent No. 11,033,495 is not valid. CEO Frank D. Lee stated that the company is considering its legal options, including pursuing an appellate review at the U.S. Court of Appeals for the Federal Circuit if warranted.

News

21 hours ago · businesswire.com

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

2 days ago · businesswire.com

Rosen Law Firm Urges Pacira BioSciences, Inc. (NASDAQ: PCRX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers or acquirers of securities of Pacira BioScie...

1 day ago · zacks.com

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

Pacira stock gains 11% on better-than-expected preliminary Q4 sales figures. It also shares a strategic growth plan to drive innovation and value creation by 2030.

2 days ago · zacks.com

Pacira (PCRX) Soars 11.1%: Is Further Upside Left in the Stock?

Pacira (PCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

6 days ago · zacks.com

FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief

Pacira receives FDA approval for a new iovera Smart Tip aimed at expanding pain management capabilities to deeper nerves like the medial branch nerve.

4 weeks ago · zacks.com

Here's Why Pacira (PCRX) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

1 month ago · zacks.com

Pacira (PCRX) Up 5.5% Since Last Earnings Report: Can It Continue?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?

1 month ago · zacks.com

PCRX Receives New Patent for Lead Pain Drug Exparel in the US

The U.S. Patent and Trademark Office grants a new patent to protect the chemical composition of Pacira's lead pain-management drug, Exparel.

1 month ago · zacks.com

Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 month ago · seekingalpha.com

Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses

Pacira BioSciences markets and sells EXPAREL, a non-opioid pain relief therapy. The drug drives revenues of >$500m per annum, but a new generic version has been approved, while Pharma giant Vertex is ...

2 months ago · zacks.com

Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth

PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.

2 months ago · seekingalpha.com

Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript

2 months ago · zacks.com

Pacira (PCRX) Q3 Earnings Beat Estimates

Pacira (PCRX) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.72 per share a year ago.